Anti- MMAE (Monomethyl Auristain E) antibody,mAb
抗MMAE鼠單克隆抗體
編號：YKMP18010
貨期：現(xiàn)貨
規(guī)格：25ug/100ug/1mg
Background
Monomethyl auristatin E (MMAE, vedotin) is a very potent antimitotic agent that inhibits cell division by blocking the polymerisation of tubulin. The family of auristatins are synthetic analogues of the antineoplastic natural product Dolastatin 10, ultrapotent cytotoxic microtubule inhibitors that are clinically used as payloads in antibody-drug conjugates. Antibody-drug conjugates enhance the antitumor effects of antibodies and reduce adverse systemic effects of highly potent cytotoxic agents.
After ADC internalization, the released MMAE in the tumor cells can enter surrounding cells and cause bystander killing [11]. This advantage of MMAE leads to an efficient killing of tumor cells. However, it can also cause toxicity to healthy cells. While MMAE-conjugated ADCs are efficacious, hematological adverse reactions such as neutropenia (≈21%) and thrombocytopenia (≈10%) are consistently reported [12,13]. Moreover, peripheral neuropathy (≈44%) is also a predominant adverse effect in the clinic (≈44%) [13,14]. It is generally believed that these toxicities stem from the pharmacological effects of the payload. However, limited studies have investigated whole-body pharmacokinetics (PK) of MMAE. While it is impossible to conduct such studies in humans due to the inherent toxicity of MMAE, preclinical studies that investigate whole-body PK of MMAE are required to better understand the disposition of this molecule and to facilitate preclinical-to-clinical translation of exposure–response relationships developed for MMAE-conjugated ADCs.
Therefore, it is very important to detect the level of MMAE before clinic. For example, the determination of the concentration of coupled MMAE in ADC, anti MMAE is necessary. Therefore, it is very important to detect the level of MMAE before clinic. For example, the determination of the concentration of coupled MMAE in ADC, antiMMAE is very convenient and fast. Of course, the PK of MMAE in ADC drugs in animal experiments is more important. Taking mice as an example, the traditional analysis may need to be through liquid phase analysis, which may have higher requirements for equipment and operation. However, when we use anti MMAE to detect the PK of mouse tumor model after administration, we have great advantages. Anti MMAE can be directly used to detect the samples to be tested and blood obtained after treatment in tissues and organs. The following is the application of anti MMAE antibody
· Study on drug delivery (ADC) of tumor cells cultured in vitro.
· Study on pharmacokinetics of animal tumor models (e.g. rats) after administration (ADC).
· Detection of MMAE in plasma of preclinical patients after administration.
相關(guān)產(chǎn)品：
Anti- MMAE (Monomethyl Auristain E) antibody,mAb-HRP 標(biāo)記
抗MMAE鼠單克隆抗體-HRP 標(biāo)記
編號：YKMP18010H
貨期：現(xiàn)貨
規(guī)格：25ul/100ul/1ml
Anti- MMAE (Monomethyl Auristain E) antibody,mAb- Biotin 標(biāo)記
抗MMAE鼠單克隆抗體-Biotin標(biāo)記
編號：YKMP1801B
貨期：現(xiàn)貨
規(guī)格：25ul/100ul/1ml
